Literature DB >> 17942928

MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines.

Bing Yang1, Sean M O'Herrin, Jianqiang Wu, Shannon Reagan-Shaw, Yongsheng Ma, Kumar M R Bhat, Claudia Gravekamp, Vijayasaradhi Setaluri, Noel Peters, F Michael Hoffmann, Hongzhuang Peng, Alexey V Ivanov, Andrew J G Simpson, B Jack Longley.   

Abstract

The MAGE-A, MAGE-B, and MAGE-C protein families comprise the class-I MAGE/cancer testes antigens, a group of highly homologous proteins whose expression is suppressed in all normal tissues except developing sperm. Aberrant expression of class I MAGE proteins occurs in melanomas and many other malignancies, and MAGE proteins have long been recognized as tumor-specific targets; however, their functions have largely been unknown. Here, we show that suppression of class I MAGE proteins induces apoptosis in the Hs-294T, A375, and S91 MAGE-positive melanoma cell lines and that members of all three families of MAGE class I proteins form complexes with KAP1, a scaffolding protein that is known as a corepressor of p53 expression and function. In addition to inducing apoptosis, MAGE suppression decreases KAP1 complexing with p53, increases immunoreactive and acetylated p53, and activates a p53 responsive reporter gene. Suppression of class I MAGE proteins also induces apoptosis in MAGE-A-positive, p53wt/wt parental HCT 116 colon cancer cells but not in a MAGE-A-positive HCT 116 p53-/- variant, indicating that MAGE suppression of apoptosis requires p53. Finally, treatment with MAGE-specific small interfering RNA suppresses S91 melanoma growth in vivo, in syngenic DBA2 mice. Thus, class I MAGE protein expression may suppress apoptosis by suppressing p53 and may actively contribute to the development of malignancies and by promoting tumor survival. Because the expression of class I MAGE proteins is limited in normal tissues, inhibition of MAGE antigen expression or function represents a novel and specific treatment for melanoma and diverse malignancies.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17942928     DOI: 10.1158/0008-5472.CAN-07-1478

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  106 in total

1.  Identification of novel small molecules that inhibit protein-protein interactions between MAGE and KAP-1.

Authors:  Neehar Bhatia; Bing Yang; Tony Z Xiao; Noel Peters; Michael F Hoffmann; B Jack Longley
Journal:  Arch Biochem Biophys       Date:  2011-01-28       Impact factor: 4.013

2.  Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103.

Authors:  Amberly Moreno-Bost; Susann Szmania; Katie Stone; Tarun Garg; Antje Hoerring; Jackie Szymonifka; John Shaughnessy; Bart Barlogie; H Grant Prentice; Frits van Rhee
Journal:  Cytotherapy       Date:  2010-12-20       Impact factor: 5.414

3.  Cancer is a somatic cell pregnancy.

Authors:  Lloyd J Old
Journal:  Cancer Immun       Date:  2007-11-06

4.  Isolation and Characterization of an HLA-DPB1*04: 01-restricted MAGE-A3 T-Cell Receptor for Cancer Immunotherapy.

Authors:  Xin Yao; Yong-Chen Lu; Linda L Parker; Yong F Li; Mona El-Gamil; Mary A Black; Hui Xu; Steven A Feldman; Pierre van der Bruggen; Steven A Rosenberg; Paul F Robbins
Journal:  J Immunother       Date:  2016-06       Impact factor: 4.456

Review 5.  Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy.

Authors:  Pierre G Coulie; Benoît J Van den Eynde; Pierre van der Bruggen; Thierry Boon
Journal:  Nat Rev Cancer       Date:  2014-02       Impact factor: 60.716

6.  Correlation of MAGE-A tumor antigens and the efficacy of various chemotherapeutic agents in head and neck carcinoma cells.

Authors:  S Hartmann; U Kriegebaum; N Küchler; R C Brands; C Linz; A C Kübler; U D A Müller-Richter
Journal:  Clin Oral Investig       Date:  2013-02-21       Impact factor: 3.573

7.  MAGE-C2 promotes growth and tumorigenicity of melanoma cells, phosphorylation of KAP1, and DNA damage repair.

Authors:  Neehar Bhatia; Tony Z Xiao; Kimberly A Rosenthal; Imtiaz A Siddiqui; Saravanan Thiyagarajan; Brendan Smart; Qiao Meng; Cindy L Zuleger; Hasan Mukhtar; Shannon C Kenney; Mark R Albertini; B Jack Longley
Journal:  J Invest Dermatol       Date:  2012-10-25       Impact factor: 8.551

8.  Cancer-testis antigens MAGE-C1/CT7 and MAGE-A3 promote the survival of multiple myeloma cells.

Authors:  Djordje Atanackovic; York Hildebrandt; Adam Jadczak; Yanran Cao; Tim Luetkens; Sabrina Meyer; Sebastian Kobold; Katrin Bartels; Caroline Pabst; Nesrine Lajmi; Maja Gordic; Tanja Stahl; Axel R Zander; Carsten Bokemeyer; Nicolaus Kröger
Journal:  Haematologica       Date:  2009-12-16       Impact factor: 9.941

9.  Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity.

Authors:  Cor Hj Lamers; Stefan Sleijfer; Sabine van Steenbergen; Pascal van Elzakker; Brigitte van Krimpen; Corrien Groot; Arnold Vulto; Michael den Bakker; Egbert Oosterwijk; Reno Debets; Jan W Gratama
Journal:  Mol Ther       Date:  2013-02-19       Impact factor: 11.454

10.  Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer.

Authors:  Ian M Smith; Chad A Glazer; Suhail K Mithani; Michael F Ochs; Wenyue Sun; Sheetal Bhan; Alexander Vostrov; Ziedulla Abdullaev; Victor Lobanenkov; Andrew Gray; Chunyan Liu; Steven S Chang; Kimberly L Ostrow; William H Westra; Shahnaz Begum; Mousumi Dhara; Joseph Califano
Journal:  PLoS One       Date:  2009-03-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.